Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ)

[1]  R. Harrison,et al.  Modulation of Osteoclastogenesis with Macrophage M1- and M2-Inducing Stimuli , 2014, PloS one.

[2]  F. Weichert,et al.  Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases , 2014, Clinical Oral Investigations.

[3]  A. Pabst,et al.  In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes , 2014, Clinical Oral Investigations.

[4]  P. Sedghizadeh,et al.  Bisphosphonate-related osteonecrosis of the jaws is caused by dental procedures that violate oral epithelium; this is no longer a mysterious disease. , 2014, Oral surgery, oral medicine, oral pathology and oral radiology.

[5]  L. Fong,et al.  Effects of RANKL-Targeted Therapy in Immunity and Cancer , 2013, Front. Oncol..

[6]  Yang Yao,et al.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials , 2014, International Journal of Clinical Oncology.

[7]  F. Biglioli,et al.  Histological findings on jaw osteonecrosis associated with bisphosphonates (BONJ) or with radiotherapy (ORN) in humans , 2013, Acta odontologica Scandinavica.

[8]  S. Ruggiero.  An office-based approach to the diagnosis and management of osteonecrosis. , 2013, Atlas of the oral and maxillofacial surgery clinics of North America.

[9]  Vijay Kumar,et al.  Evolution and Etiopathogenesis of Bisphosphonates Induced Osteonecrosis of the Jaw , 2013, North American journal of medical sciences.

[10]  F. Saad,et al.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.

[11]  Petko Ivanov,et al.  A single-dose study of denosumab in patients with various degrees of renal impairment , 2012 .

[12]  C. Scully,et al.  Denosumab-related osteonecrosis of the jaw. , 2012, Journal of the American Dental Association.

[13]  P. Kostenuik,et al.  Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.

[14]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Rogers,et al.  Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  M. Glogauer,et al.  Zoledronate and pamidronate depress neutrophil functions and survival in mice , 2012, British journal of pharmacology.

[17]  R. Consolini,et al.  Zoledronic acid modulates maturation of human monocyte-derived dendritic cells , 2011, Experimental biology and medicine.

[18]  R. Russell,et al.  Bisphosphonates: the first 40 years. , 2011, Bone.

[19]  R. Baron,et al.  Denosumab and bisphosphonates: different mechanisms of action and effects. , 2011, Bone.

[20]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[22]  M. Pazianas.  Osteonecrosis of the jaw and the role of macrophages. , 2011, Journal of the National Cancer Institute.

[23]  S. Ferrari-Lacraz,et al.  Do RANKL inhibitors (denosumab) affect inflammation and immunity? , 2011, Osteoporosis International.

[24]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Al-Nawas,et al.  Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients , 2010, Head & face medicine.

[26]  T. Yoneda,et al.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral , 2010, Journal of Bone and Mineral Metabolism.

[27]  Markus G. Manz,et al.  Development of Monocytes, Macrophages, and Dendritic Cells , 2010, Science.

[28]  Marc Daigneault,et al.  The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages , 2010, PloS one.

[29]  Reinhard Hickel,et al.  Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. , 2010, Dental Materials.

[30]  M. Wirth,et al.  Alteration of the glycosylation pattern of monocytic THP-1 cells upon differentiation and its impact on lectin-mediated drug delivery. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  E. Maiorano,et al.  Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. , 2009, Bone.

[32]  D. Burr,et al.  Mandibular necrosis in beagle dogs treated with bisphosphonates. , 2009, Orthodontics & craniofacial research.

[33]  L. Assael,et al.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[34]  S. Chevalier,et al.  Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. , 2007, Biochemical pharmacology.

[35]  Steven W. Martin,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  S. Hoefert,et al.  [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. , 2005, Mund-, Kiefer- und Gesichtschirurgie : MKG.

[37]  H. Eufinger,et al.  Kieferknochennekrosen als mögliche unerwünschte Wirkung von Bisphosphonaten , 2005, Mund-, Kiefer- und Gesichtschirurgie.

[38]  A. Sewell,et al.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins , 2005, Clinical and experimental immunology.

[39]  N. van Bruggen,et al.  A Novel in Vivo Role for Osteoprotegerin Ligand in Activation of Monocyte Effector Function and Inflammatory Response* , 2004, Journal of Biological Chemistry.

[40]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[41]  M. Wilhelm,et al.  Gamma/delta T-cell stimulation by pamidronate. , 1999, The New England journal of medicine.

[42]  J. Lawry,et al.  Bisphosphonates induce apoptosis in mouse macrophage‐like cells in vitro by a nitric oxide‐independent mechanism , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.